Notably, patients with poor LIPI scores show significantly worse outcomes independent of their PD-L1 tumor proportion score (TPS), suggesting LIPI’s superior predictive value in chemoimmunotherapy contexts. The gene discussed is CD274; the disease is neoplasm.